Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy

Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells

“…However, the high AR staining scores was associate smaller tumor size. These findings are consistent with those reported by Soong [19] and Boix [20] et al We then examined AR and CD90 staining score in the primary tumor using serial sections. We found that AR and CD90 expression are inversely expression.…”

“…Theoretically, the cellular characteristics of hepatectomy patients are considered in the early developmental stages of cancer, but can exhibit characteristics that have been shown to be associated with recurrence, which implies that tumor heterogeneity exists even in the early stages of cancer [32]. Prognostic factors such as tumor size, TNM stage, and AFP levels are not sufficient predictors of HCC recurrence after hepatectomy [19]. Colonization of surviving tumor cells in the circulation is one hypothesis for HCC recurrence [16].…”

Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis

“…Less than 30% of HCC patients are eligible for curative procedures at the time of diagnosis and hepatic recurrence occurs in more than 50% of patients treated with curative measures . More accurate detection of HCC at an earlier stage of disease may reduce the risk of tumor recurrence and this is the focus of much diagnostic research …”

“…[2][3][4] In contrast, later stage disease is treated with palliative intent and survival is markedly lower. The median survival rate for intermediate stage HCC (multinodular lesions) following transcatheter arterial chemoembolization (TACE) is 20 months (range 14-45 months) and the median 5-year survival following advanced stage HCC (portal invasion) treated with chemotherapy is 11 months (range [6][7][8][9][10][11][12][13][14]. 2 Less than 30% of HCC patients are eligible for curative procedures at the time of diagnosis 5,6 and hepatic recurrence occurs in more than 50% of patients treated with curative measures.…”

“…[7][8][9][10] More accurate detection of HCC at an earlier stage of disease may reduce the risk of tumor recurrence and this is the focus of much diagnostic research. 11,12 Current imaging modalities for characterizing liver lesions include contrast-enhanced computed tomography (CE-CT) and magnetic resonance imaging (MRI). 13 Dynamic MRI (D-MRI) imaging should include arterial phase, portal venous phase, and delayed phase imaging, which can be conducted using extracellular contrast agents, for example, gadopentetic acid (Gd-DTPA, GP).…”